BioCentury | Apr 28, 2020
Product Development

Blueprint stumbles in GIST race, clearing path for Deciphera

...investor call. The median PFS for avapritinib was 4.2 months vs. 5.6 months for Stivarga regorafenib...
...PDGFRA inhibitor showing a 17% overall response rate (ORR) vs. 7% in the Stivarga group. Stivarga...
...not be as effective as therapies that hit a wider array of kinases such as Stivarga...
BioCentury | Aug 13, 2019
Clinical News

Big gain for Deciphera as GIST readout portends face-off with Blueprint

...INVICTUS tested ripretinib in patients who had previously received Gleevec imatinib, Sutent sunitinib and Stivarga regorafenib...
...or more would be "clinically meaningful" in INVICTUS. Data in the labels of Sutent and Stivarga...
...and a confirmed ORR of 22%. Blueprint's Phase III VOYAGER study is comparing avapritinib with Stivarga...
BioCentury | Jun 19, 2019
Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

...to the group, will use Bayesian analyses to simultaneously evaluate multiple drugs, starting with Stivarga regorafenib...
...2 BioCentury Staff Constella, Linzess, linaclotide (ASP0456, MD-1100) Lokelma, sodium zirconium cyclosilicate (ZS-9) OSE-172 (BI765063, Effi-Dem) Stivarga, fluoro-sorafenib, regorafenib (BAY 73-4506, DAST Inhibitor) trilaciclib...
BioCentury | May 10, 2019
Product Development

Exelixis to fuel pipeline growth with Cabometyx cash flows

...plus Tecentriq did not meet its primary endpoint of improved overall survival compared to Stivarga regorafenib...
BioCentury | Mar 23, 2019
Tools & Techniques

A frequentist and a Bayesian walk into a trial

...way for Bayesian analyses of multiple GBM drugs. Its first candidate is Bayer AG’s Stivarga regorafenib...
BioCentury | Nov 16, 2018
Clinical News

Blueprint reports 84% ORR for avapritinib in PDGFRα D842V-driven GIST

...CD140A) with the D842V amino acid substitution. Blueprint also reported that among 23 evaluable Stivarga regorafenib-naïve...
...led to an ORR of 25%. The Phase III VOYAGER trial is comparing avapritinib to Stivarga...
BioCentury | Nov 16, 2018
Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

...Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be...
...Global Coalition for Adaptive Research (GCAR), Lexington, Mass. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Stivarga regorafenib...
...OS) Status: Phase II/III start Milestone: Phase II/III start (early 2019) Jennie Walters Stivarga, fluoro-sorafenib, regorafenib (BAY 73-4506, DAST Inhibitor) Bayer...
BioCentury | Nov 14, 2018
Clinical News

Bayer's Stivarga first to enter adaptive brain cancer trial

...Bayer AG (Xetra:BAYN) and the Global Coalition for Adaptive Research (GCAR) said Stivarga regorafenib will be...
...said too many factors come into play to estimate how long it will take for Stivarga...
...is a dual acting signal transduction (DAST) inhibitor of multiple kinases. Jennie Walters Stivarga, fluoro-sorafenib, regorafenib (BAY 73-4506, DAST Inhibitor) Bayer...
BioCentury | Oct 10, 2018
Politics & Policy

China adds insurance coverage for 17 cancer therapies

...Inc. (NYSE:PFE) for myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia and acute myelogenous leukemia (AML); Stivarga regorafenib...
...Jakafi (Other) Mycapssa, octreotide (RG3806, octreolin) Ninlaro (Brand), MLN9708, ixazomib (Generic), Ninlaro (Other) Oncaspar, pegaspargase Stivarga, fluoro-sorafenib, regorafenib (BAY 73-4506, DAST Inhibitor) Sutent...
BioCentury | Aug 17, 2018
Politics & Policy

China unveils cancer drugs for medical insurance access negotiation

...Novartis for RCC and soft tissue sarcoma (STS); Sutent sunitinib from Pfizer for RCC; Stivarga regorafenib...
Items per page:
1 - 10 of 119